Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Pharvaris. The associated price target remains the same with $60.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Pharvaris’s deucrictibant immediate-release capsule for treating hereditary angioedema (HAE) attacks. The positive results from the Phase 3 RAPIDe-3 trial demonstrated that the drug met its primary endpoint with a significantly faster onset of symptom relief compared to placebo. Additionally, all secondary efficacy endpoints were achieved with high statistical significance, and the drug exhibited a strong safety profile, reinforcing its potential as a best-in-class oral therapy.
Trucchio also notes the trial’s comprehensive inclusion of a diverse patient population, which underscores the drug’s broad applicability. The rapid efficacy and minimal need for rescue medication further support its potential to change the treatment landscape for HAE. Looking ahead, the anticipated 2026 NDA submission and subsequent clinical trials provide additional opportunities for Pharvaris to expand its therapeutic offerings, potentially establishing deucrictibant as a leading oral therapy in both acute and preventative settings. These factors, combined with a robust valuation approach, underpin Trucchio’s Buy rating with a price target of $60 per share.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $43.00 price target.